Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MaxCyte Inc.

www.maxcyte.com

Latest From MaxCyte Inc.

Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology

Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK

Deals Business Strategies

Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deals Coronavirus COVID-19

What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

BioPharmaceutical Business Strategies

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • TheraMed Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MaxCyte Inc.
  • Senior Management
  • Douglas A Doerfler, Pres. & CEO
    Ronald Holtz, CFO
    Deborah K Bowes, EVP, Bus. & Strategic Dev.
    Madhusudan Peshwa, PhD, CSO, EVP, Cellular Therapies
    Thomas M Ross, EVP, Global Sales
  • Contact Info
  • MaxCyte Inc.
    Phone: (301) 944-1700
    22 Firstfield Road
    St. 250
    Gaithersburg, MD 20878
    USA
UsernamePublicRestriction

Register